EMA highlights Neolish vaccine against leishmaniasis in dogs as one of the outstanding medicines authorized in 2022

The European Medicines Agency (EMA) has published a summary highlighting its actions on the authorization and safety monitoring of veterinary medicinal products in 2022. Neoleish, a vaccine developed in the laboratory of Prof. Vicente Larraga at the Margarita Salas Center for Biological Research, has been recognized as one of the particularly relevant animal health innovations of the year.

The report lists the ten drugs authorized commercially in 2022. Of these, three are based on a new active substance, two being vaccines.

Neoleish is a plasmid DNA vaccine for active immunization of Leishmania-negative dogs from 6 months of age to reduce the risk of developing active infection and/or clinical disease following exposure to Leishmania infantum.

More information:

EMA report: link.

Press release of the Neoleish vaccine authorization: link.